{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T03:15:55Z","timestamp":1773717355342,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ijrobp.2024.11.071","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T11:16:41Z","timestamp":1731755801000},"page":"1229-1236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Docetaxel\/Cisplatin Chemotherapy Followed by Pelvic Radiation Therapy in Patients With High-risk Endometrial Cancer After Staging Surgery: A Phase 2 Study"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4574-5124","authenticated-orcid":false,"given":"Ok-Ju","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon-Jung","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myong Cheol","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeon Jee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Soo","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sokbom","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Yoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joo-Hyun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong-Yeol","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.11.071_bib0001","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/cncr.32802","article-title":"Annual report to the nation on the status of cancer, part I: National cancer statistics","volume":"126","author":"Henley","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0002","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.3802\/jgo.2019.30.e38","article-title":"Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999-2015","volume":"30","author":"Lim","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0003","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0004","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4143\/crt.2022.179","article-title":"Prediction of cancer incidence and mortality in Korea, 2022","volume":"54","author":"Jung","year":"2022","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0005","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4143\/crt.2021.290","article-title":"Prediction of cancer incidence and mortality in Korea, 2021","volume":"53","author":"Jung","year":"2021","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0006","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2014.06.003","article-title":"Endometrial cancer: A review and current management strategies: Part II","volume":"134","author":"Clinical Practice Endometrial Cancer Working Group","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0007","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/GCO.0000000000000832","article-title":"Alarming trends and disparities in high-risk endometrial cancer","volume":"35","author":"Eakin","year":"2023","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0008","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/AOG.0b013e3181f39849","article-title":"Comparative performance of the 2009 International Federation of Gynecology and Obstetrics\u2019 staging system for uterine corpus cancer","volume":"116","author":"Lewin","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0009","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00280-013-2276-9","article-title":"Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: Results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology)","volume":"72","author":"Mustea","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0010","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ygyno.2013.09.012","article-title":"The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma","volume":"131","author":"Jutzi","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0011","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1525-1438.2006.00746.x","article-title":"Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: A large retrospective study","volume":"17","author":"Sovak","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0012","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ygyno.2008.01.028","article-title":"Carboplatin and paclitaxel in advanced or metastatic endometrial cancer","volume":"109","author":"Pectasides","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0013","first-page":"803","article-title":"Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up","volume":"18","author":"Sorbe","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0014","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1200\/JCO.2004.02.088","article-title":"Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A gynecologic oncology group study","volume":"22","author":"Thigpen","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0015","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/annonc\/mdq401","article-title":"Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: A Japanese Gynecologic Oncology Group study (JGOG2041)","volume":"22","author":"Nomura","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0016","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/sj.bjc.6602817","article-title":"Phase II trial of docetaxel in advanced or metastatic endometrial cancer: A Japanese Cooperative Study","volume":"93","author":"Katsumata","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0017","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/0090-8258(89)90605-7","article-title":"Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study","volume":"33","author":"Thigpen","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0018","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00000421-198406000-00010","article-title":"Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group Study","volume":"7","author":"Thigpen","year":"1984","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0019","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): Final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0020","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6603279","article-title":"Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial","volume":"95","author":"Maggi","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0021","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S0360-3016(01)01566-8","article-title":"Significant pelvic recurrence in high-risk pathologic stage I\u2013IV endometrial carcinoma patients after adjuvant chemotherapy alone: Implications for adjuvant radiation therapy","volume":"50","author":"Mundt","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0022","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ygyno.2012.10.010","article-title":"A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer","volume":"128","author":"Secord","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0023","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ygyno.2006.02.007","article-title":"Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin\/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer","volume":"103","author":"Greven","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0024","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0025","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003777","volume":"10","author":"Oaknin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0026","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2024.11.071_bib0027","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624036472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624036472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:51:17Z","timestamp":1762296677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301624036472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0360301624036472"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.11.071","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Docetaxel\/Cisplatin Chemotherapy Followed by Pelvic Radiation Therapy in Patients With High-risk Endometrial Cancer After Staging Surgery: A Phase 2 Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.11.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}